GRI Bio Says Growing Body Of Phase 2a Clinical, Translational And Biomarker Data Continues To Reinforce GRI-0621's Differentiated Therapeutic Potential In Idiopathic Pulmonary Fibrosis

Benzinga Newsdesk www.benzinga.com Positive 95.4%

Neg 0% Neu 0% Pos 95.4%

Comments

No comments yet. Be the first!